BLRD Research Career Scientist Award Application

本申请表是为苏布拉·莫哈帕特拉博士颁发的研究职业科学家奖 (提名)他是佛罗里达州坦帕市詹姆斯·A·黑利退伍军人医院的研究微生物学家， 南佛罗里达大学退伍军人事务部附属学术中心副教授。自.以来 2007年，被提名人通过培训为退伍军人管理局的研究和服务做出了重大贡献， 指导和与退伍军人管理局调查人员的合作。她在国内和国际上都是公认的 她在肿瘤生物学领域的贡献，特别是关于肿瘤机制的贡献- 基质相互作用、基于3D培养的抗癌药物发现和纳米抗癌药物 快要送货了。她对科学文献做出了重大贡献，包括超过61 出版物，产生了约2419次引用，累计H指数为28，i10指数 45岁。她还拥有12项美国专利。莫哈帕特拉博士接受了大量的校外研究 支持(约1300万美元)，包括来自NIH、ONR、退伍军人事务部和 佛罗里达州卫生局。她还担任过《药物传递和治疗杂志》的客座编辑。 翻译研究(控释学会杂志)特刊《纳米生物》 界面：从实验室到诊所。她被《佛罗里达高科技报》选为《科技面孔》 并被美国联邦科学基金会研究办公室授予2014年度卓越创新奖 和创新。莫哈帕特拉博士获得了两项功绩评审奖的资助。她已经发起了 未来功绩提案的第三个项目。由退伍军人事务部功绩审查支持的当前研究活动 (VMR)摘要如下。 VMR项目1(2016-2019年)。研究一种新的组合疗法的潜力 在中度创伤性脑损伤大鼠模型中的方法，包括(I)减轻炎症(局部)的治疗 和系统)使用针对新近发现的靶CCL20的纳米配方的siRNA，和(Ii) 通过间充质干细胞(MSC)治疗促进神经再生的第二种治疗方法。 VMR项目2(2017-2021年)。一种新型靶向溶瘤病毒细胞的潜能研究 应用呼吸道合胞病毒(RSV)感染的MSCs治疗肺部疾病 癌症。该项目包括用野生型或突变型RSV感染hMSCs，并在体外进行测试。 使用3D类肿瘤平台，然后利用免疫活性测试其抗癌能力 同种异体肺癌原位移植模型。此外，她还在第三个VMR项目中担任协理 专注于RSV。 项目3(VMR项目正在开发中)。发现和调查小说的潜力 针对肿瘤干细胞(CSCs)的抗癌药物，用于治疗结直肠癌(CRC)。 该项目涉及使用3D类肿瘤平台来筛选将抑制 体外扩增CRC-CSCs并检测其对小鼠的治疗作用 CRC。 这些高度创新的项目加在一起，预计将产生很大的影响 为退伍军人和其他有需要的美国人提供各种疾病的治疗方法。总而言之，Dr。 Mohapatra作为一名研究职业科学家将非常有效地在 退伍军人事务部的培训、指导、研究和服务。

This application is for a Research Career Scientist Award for Dr. Subhra Mohapatra (nominee) who is a research microbiologist at the James A. Haley VA Hospital, Tampa, FL, and an Associate Professor at the VA-affiliated academic center, the University of South Florida. Since 2007, the nominee has been contributing significantly to VA research and services via training, mentoring and collaboration with VA investigators. She is recognized nationally and internationally for her contributions to the field of tumor biology, particularly pertaining to mechanism of tumor- stroma interactions, 3D culture-based anti-cancer drug discovery, and nanoscale anti-cancer drug delivery approaches. She has contributed significantly to scientific literature including over 61 publications, which have generated ~2419 citations and a cumulative H-Index of 28 and i10-Index of 45. She also holds 12 US patents. Dr. Mohapatra has received substantial extramural research support (~$13 million) including awards from the NIH, ONR, Department of Veterans Affairs and Florida Department of Health. She also served as guest editor of the Journal of Drug Delivery and Translational Research (a journal of the Controlled Release Society) special issue entitled “NanoBio Interface: From Lab to Clinic.” She was selected for “Faces of Technology” by the Florida High Tech Corridor and was awarded the 2014 Excellence in Innovation award by the USF Office of Research and Innovation. Dr. Mohapatra has been funded with the two Merit Review Awards. She has initiated a third project for a future Merit proposal. Current research activities supported by VA Merit Review (VMR) are summarized below. VMR Project #1 (2016-2019). Investigate the potential of a novel combinatorial therapeutic approach in a rat model of moderate TBI that includes (i) a treatment to reduce inflammation (local and systemic) using a nano-formulated siRNA against a recently discovered target, CCL20, and (ii) a second treatment to promote neuroregeneration by mesenchymal stem cell (MSC) therapy. VMR Project #2 (2017-2021). Investigate the potential of a novel targeted oncolytic viro-cell therapy using MSCs infected by a common cold virus, respiratory syncytial virus (RSV), for lung cancers. The project involves infecting hMSCs with wild type or mutant RSV and testing them in vitro using 3D tumoroid platform and then testing their anti-cancer potential using immunocompetent syngeneic orthotopic model of lung cancer. In addition, she serves as a co-I in a third VMR project that focuses on RSV. Project #3 (VMR project in development). Discover and investigate the potential of novel anticancer agents targeting cancer stem cells (CSCs) for the treatment of colorectal cancer (CRC). The project involves use of 3D tumoroid platform to screen for anticancer agents that will inhibit expansion of CRC-CSCs and then testing therapeutic efficacy of these agents in mouse model of CRCs. These highly innovative programs taken together are expected to lead to high impact therapies for diverse diseases for Veterans and other Americans in need. In summary, Dr. Mohapatra will be highly effective as a Research Career Scientist creating national impacts in training, mentoring, research and services at the VA.